Bliss GVS Pharma Ltd
Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.
- Market Cap ₹ 1,187 Cr.
- Current Price ₹ 113
- High / Low ₹ 150 / 75.4
- Stock P/E 12.6
- Book Value ₹ 92.4
- Dividend Yield 0.45 %
- ROCE 14.4 %
- ROE 10.2 %
- Face Value ₹ 1.00
Pros
- Stock is trading at 1.17 times its book value
Cons
- The company has delivered a poor sales growth of -3.04% over past five years.
- Promoter holding is low: 35.0%
- Company has a low return on equity of 7.46% over last 3 years.
- Company has high debtors of 192 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
397 | 345 | 407 | 547 | 798 | 815 | 899 | 689 | 577 | 747 | 752 | 770 | |
285 | 273 | 304 | 391 | 596 | 618 | 739 | 566 | 471 | 629 | 634 | 620 | |
Operating Profit | 111 | 71 | 103 | 156 | 203 | 197 | 160 | 123 | 107 | 118 | 117 | 151 |
OPM % | 28% | 21% | 25% | 29% | 25% | 24% | 18% | 18% | 18% | 16% | 16% | 20% |
14 | 28 | 20 | 24 | 12 | -8 | 35 | 26 | 20 | -42 | 18 | -0 | |
Interest | 10 | 18 | 16 | 19 | 20 | 23 | 4 | 8 | 6 | 5 | 10 | 7 |
Depreciation | 6 | 11 | 11 | 13 | 20 | 21 | 9 | 13 | 17 | 17 | 19 | 26 |
Profit before tax | 109 | 71 | 96 | 148 | 175 | 145 | 182 | 129 | 104 | 54 | 106 | 117 |
Tax % | 46% | 42% | 36% | 32% | 36% | 39% | 30% | 26% | 29% | 57% | 28% | 30% |
60 | 41 | 61 | 100 | 113 | 89 | 127 | 95 | 74 | 23 | 77 | 82 | |
EPS in Rs | 5.60 | 3.97 | 5.81 | 8.00 | 7.95 | 5.70 | 11.99 | 9.43 | 6.64 | 1.45 | 6.80 | 7.21 |
Dividend Payout % | 12% | 13% | 12% | 6% | 8% | 18% | 8% | 5% | 8% | 34% | 7% | 7% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | -3% |
3 Years: | 10% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | -6% |
3 Years: | 11% |
TTM: | 33% |
Stock Price CAGR | |
---|---|
10 Years: | 7% |
5 Years: | -8% |
3 Years: | -3% |
1 Year: | 36% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 9% |
3 Years: | 7% |
Last Year: | 10% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Reserves | 248 | 277 | 327 | 402 | 476 | 526 | 636 | 725 | 798 | 808 | 873 | 957 |
148 | 173 | 160 | 132 | 225 | 118 | 102 | 126 | 122 | 109 | 102 | 100 | |
165 | 123 | 166 | 218 | 311 | 206 | 157 | 168 | 147 | 181 | 171 | 147 | |
Total Liabilities | 571 | 583 | 662 | 762 | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,157 | 1,214 |
168 | 213 | 234 | 225 | 305 | 143 | 146 | 242 | 234 | 281 | 379 | 370 | |
CWIP | 1 | 4 | 0 | 9 | 4 | 0 | 47 | 0 | 2 | 22 | 3 | 8 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 8 | 4 |
402 | 365 | 428 | 527 | 714 | 717 | 712 | 788 | 840 | 803 | 768 | 832 | |
Total Assets | 571 | 583 | 662 | 762 | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,157 | 1,214 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
6 | 41 | 38 | 113 | 289 | 18 | 40 | 47 | 64 | 135 | 34 | 152 | |
-124 | -11 | -29 | -50 | -249 | 48 | -79 | -40 | -45 | -103 | -6 | -133 | |
110 | -8 | -42 | -40 | -10 | -76 | 17 | -6 | -21 | -24 | -25 | -21 | |
Net Cash Flow | -8 | 22 | -34 | 23 | 30 | -10 | -22 | 0 | -2 | 9 | 3 | -1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 225 | 228 | 222 | 201 | 116 | 134 | 187 | 290 | 293 | 192 | 187 | 192 |
Inventory Days | 58 | 70 | 69 | 55 | 50 | 55 | 46 | 64 | 110 | 116 | 94 | 113 |
Days Payable | 212 | 176 | 165 | 153 | 100 | 55 | 47 | 75 | 82 | 86 | 79 | 58 |
Cash Conversion Cycle | 71 | 121 | 126 | 102 | 67 | 134 | 186 | 279 | 321 | 221 | 202 | 247 |
Working Capital Days | 130 | 146 | 160 | 125 | 76 | 182 | 180 | 269 | 319 | 219 | 221 | 233 |
ROCE % | 35% | 20% | 23% | 31% | 29% | 27% | 26% | 18% | 12% | 14% | 12% |
Documents
Announcements
- Business Responsibility and Sustainability Reporting (BRSR) 15h
- Notice Of The 39Th Annual General Meeting ('AGM') Of Bliss GVS Pharma Limited 15h
- Reg. 34 (1) Annual Report. 16h
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Copies of the newspaper notice in the interest of the shareholders regarding the intimation of 39th Annual General Meeting of the Company scheduled to be …
- Closure of Trading Window 28 Jun
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:
a) Pharma Products:[1]
Capsules, Creams/Gels/Ointments, Dry Powder for Injection and for Oral Suspension, Eye/Ear Drops, Effervescent tablets, Lotions, Injections, Liquid Preparations, Lozenges, Nasal Solutions, Oral Solids, Parenteral, etc.
b) Other Healthcare Products:[2]
Balm, Cream, Lotion, OTC products, Petroleum Jelly, Powder, Roll On
c) Therapeutics:[3]
Analgesic, Antacid, Anti-malarial, Anti-fungal, Anti-bacterial, Anti-biotic, Anti-inflammatory, Anti-diarrheic, anti-diabetic, etc.